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Introduction. Respiratory cancer and its treatment are known to contribute to muscle weakness and functional impairment. Aim.
To assess the eﬀects of rehabilitation in patients with respiratory cancer. Methods. Radically treated respiratory cancer patients
were included in a 12-week multidisciplinary rehabilitation program. Results. 16 patients (age: 61 ± 7 years; FEV1: 57 ± 16%
pred.) showed a reduced exercise tolerance (VO2max: 56 ± 15% pred.; 6 MWD: 67 ± 11% pred.), muscle force (PImax: 54 ± 22%
pred.; QF: 67 ± 16% pred.), and quality of life (CRDQd: 17 ± 5 points; CRDQf: 16 ± 5 points). Exercise tolerance, muscle force,
and quality of life improved significantly after rehabilitation. Conclusion. Radically treated patients with respiratory cancer have
a decreased exercise capacity, muscle force, and quality of life. 12 weeks of rehabilitation leads to a significant improvement in
exercise capacity, respiratory muscle force, and quality of life.
1. Introduction
Radical treatment for early-stage lung cancer and mesothe-
lioma consists of combinations of surgery, chemotherapy,
and radiation therapy [1]. Resection of lung parenchyma
reduces pulmonary volumes and exercise tolerance [2].
Chemotherapy (e.g., taxanes, cisplatin) may induce periph-
eral sensory neuropathy, which can persist for months to
years [3]. Radiotherapy, given at doses of 50–66 Gray (Gy),
may lead to a functional loss of lung parenchyma, radiation-
induced pneumonitis and esophagitis, causing a temporary
reduction in food intake. All these treatments are known
to contribute to muscle weakness, muscle atrophy, and
functional impairment [3–5].
Endurance training has been mostly proposed as a
promising strategy in the management of the physical
and psychological deterioration in cancer patients. Physical
functioning, health-related quality of life (HRQOL), and
cancer-related fatigue improve by training in these patients
[6, 7].
Two small observational studies suggest that patients
with lung cancer may also benefit from posttreatment
rehabilitation. Spruit et al. [8] reported that an 8-week
inpatient rehabilitation program increased the 6MWD in 10
patients after lung cancer treatment. Another study described
that 14 weeks of outpatient rehabilitation improved maximal
exercise capacity and the HRQOL in 19 patients [9]. A case-
controlled study [10] in 25 lung cancer patients treated by
surgery only demonstrated also a significant improvement in
6MWD after a 4-week in-patient rehabilitation program.
In these three studies, rehabilitation consisted of endur-
ance training. In none of these trials, muscle force was
assessed nor was resistance exercise training proposed,
although more than 65% of patients reported leg fatigue
or a combination of leg fatigue and dyspnea as the major
symptom at the end of exercise [9].
The present study was designed to investigate (1) whether
and to which extent the exercise tolerance, peripheral and
respiratory muscle strength, body composition, and dyspnea
and fatigue improved by a 12-week outpatient multidisci-
plinary rehabilitation program, consisting of both resistance
and endurance exercise training in patients with radically
treated respiratory cancer; (2) whether exercise tolerance
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after radical treatment was related to peripheral muscle force
and mass.
2. Materials and Methods
2.1. Study Design and Population. The present study was
a prospective nonrandomized observational pilot study,
conducted in patients with NSCLC or mesothelioma, who
were candidate for radical treatment. Radical treatment was
defined as surgical resection with or without perioperative
chemotherapy, and/or as thoracic radiotherapy with or with-
out chemotherapy. At time point of inclusion, participants
had to be radically treated, had to be younger than 75 years,
present with a completely normalized blood analysis and
exhibit a forced expiratory volume (FEV1) <60% of the
predicted value, andmet at least two of the following criteria:
a maximal workload (Wmax) <90Watt, a 6MWD <70% of
the predicted value, <100 points on the chronic respiratory
disease questionnaire (CRDQ) or <20 points on the domain
dyspnea (CRDQd), and a quadriceps force (QF) <70% of the
predicted value or an inspiratory muscle force (PImax) or
an expiratory muscle force (PEmax) <70% of the predicted.
They all give written informed consent. Patients with
severe cardiac, neurological, and orthopaedic comorbidity
interfering with exercise training were excluded. The design
of the study was approved by the Ethics Committee of the
University Hospital Ghent.
2.2. Evaluation. Forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), diﬀusion capacity in
lung (DL,CO) were measured following the ERS guidelines
for pulmonary function testing (Viasys Sensor medics VMAX,
spectra, USA) [11]. Results were expressed as percentages of
predicted values [12].
Body Composition was assessed using a single frequency
(50 kHz) bioelectrical impedance device (Bodystat 1500
Medical, Isle of Man, LTD). The electrical current was
applied to the skin through four adhesives electrodes
attached to the right dorsal side of wrist and foot, while
the patient was in supine position. Body mass index (BMI)
was defined from height and weight. The Fat Free Mass
index (FFMI) was calculated as the ratio of FFM (Fat Free
Mass) to height in squared meters. Nutritional depletion was
defined as BMI ≤20 kg/m2 and/or FFMI ≤15 (females) or
≤16 (males) kg/m2[13].
Maximal Exercise Capacity (Wmax) was assessed by an
incremental symptom-limited exercise test (Jaeger cycle-ergo
meter). Heart rate, blood pressure, and oxygen saturation
were continuously monitored during the procedure. After
3 minutes of unloaded pedalling, workload was increased
by 10 Watt/min until exhaustion. Oxygen consumption,
carbon dioxide output, and ventilation weremeasured breath
by breath. Maximal oxygen consumption (VO2max) was
compared with normal values [14]. Exercise limitation
was determined according to the ATS/ACCP guidelines for
cardiopulmonary exercise testing [15].
6 Minute Walking Distance (6MWD) was measured
according to the ATS-guidelines [16]. Oxygen saturation
was measured continuously. The best out of 3 attempts was
retained and expressed as a percentage of the predicted value
[17].
Inspiratory and Expiratory Muscle Strength (PImax and
PEmax) was determined according to the method of Black
and Hyatt [18]. Expiratory muscle strength was measured
starting from TLC and inspiratory muscle strength starting
from RV. Tests were repeated until the variability among
three attempts was less than 5%. The highest value was
expressed as a percentage of the predicted value [19].
Hand-Grip Force (HGF) was measured using a hydraulic
hand dynamometer. (Jamar Preston, Jackson, MI, USA).
Peak HGF was assessed at the dominant side with the elbow
at 90◦ flexion, with the undergroup and wrist in neutral
position. Three attempts were performed and the highest
value was taken for analysis and expressed as a percentage
of the predicted value [20].
Isometric Quadriceps Force (QF) was measured using
an isometric handheld dynamometer (Microfet; Biometrics,
Almere, the Netherlands) attached on a knee pendicular
bank. Extension peak torque was evaluated at 60◦ of knee
flexion. Patients were asked to perform a 5 seconds isometric
contraction. The best out of three attempts was retained and
expressed as a percentage of the predicted value [21].
Dyspnea and Fatigue were assessed using the domains
“dyspnea” and “fatigue” of the validated Dutch translation
of the CRDQ (Chronic Respiratory Disease Questionnaire)
[22].
2.3. Multidisciplinary Rehabilitation Program. At intake,
every patient was examined by a pulmonologist, a physio-
therapist, a social worker, a nutritionist, a psychologist, and
an occupational therapist. All programs were individually
tailored. Each rehabilitation session consisted of 60 minutes
of reconditioning and 30 minutes of occupational therapy,
nutritional support, or psychosocial support depending on
the personal needs of every patient.
Exercise training included bicycle training, treadmill
walking, stair climbing, and peripheral muscle training on
Technogym equipment (leg press, leg extension, abduction
and adduction, the vertical row, vertical tracker, and chest
press). Resistance training for peripheral muscles of the
upper and lower extremity started with 3 series of 10
repetitions at 50% of the 1 RM (one Repetition Maximum,
weight that could be lifted once). Subsequently, the resistance
was progressively increased to 80% of the 1 RM to reach
a Borg score of 4–6 for dyspnea or fatigue [23]. New 1
RMmeasurements were performed after 6 weeks. Endurance
training consisted of walking on a treadmill and cycling on a
bicycle ergometer. Treadmill training intensity started at 70%
of the average speed of the 6MWD for 6 minutes in the first
week and was subsequently enhanced by increasing duration,
speed, and eventually slope. Bicycle training intensity started
at 70% of the average workload of the maximal incremental
test for 10 minutes and the duration and load were
progressively enhanced until the 12th week. During each
session, workload and maximal walking speed were adapted
to reach a Borg score between 4 and 6 for dyspnea and fatigue
[23].
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Figure 1: Correlation between maximal exercise capacity and
muscle force.
We systematically prescribed nutritional support by
dietary advice and oral nutritional supplements in accor-
dance with criteria proposed in other studies: BMI
<18.5 kg/m2; unintentional weight loss >10% within the last
3–6 months; or BMI <20 kg/m2 and unintentional weight
loss >5% within the last 3–6 months [24].
2.4. Data Analysis. The change in 6MWD after 12 weeks was
used as primary outcome. Changes in QF, PImax, PEmax,
HGF, VO2max, Wmax, FFM, FFMI, CRDQd, and CRDQf
were secondary outcomes. The analysis was performed using
nonparametric statistics of the Statistical Package for the
Social Sciences (SPSS 15.0). The Wilcoxon test was used to
see a diﬀerence between the variables at intake and after 12
weeks. A significant level of P < 0.05 was used through-
out the data analysis. Clinically relevant improvements in
6MWD, Wmax, and CRDQd were defined as a progression
exceeding 54m, 10Watt, and 2.5 points, respectively [25–27].
Spearman analysis was used to detect correlations between
the exercise capacity and the muscle force and mass. All
values are expressed as means and standard deviations (SD).
3. Results
All 16 patients, included in the study (Male: 13; age: 61 ±
7 years; FEV1: 57 ± 15% pred.; FVC: 66 ± 28% pred.;
DL, CO: 43 ± 15% pred.) completed the entire 12 week
training program. They were all considered to be radically
treated at intake. Ten out of 16 patients were diagnosed with
NSCLC, 4 patients were diagnosed with mesothelioma and
two with a carcinoid tumour. Nine patients underwent a
pneumonectomy and five a lobectomy. Eleven of them were
treated with either adjuvant chemotherapy or radiotherapy
(Table 1). Intake for rehabilitation took place 18 ± 4 weeks
after completion of radical treatment. Adverse eﬀects were
not reported.
Maximal exercise testing at baseline revealed that eight
patients reached their maximal predicted ventilation and
one patient his maximal predicted heart rate. The remaining
seven patients performed also a maximal exercise test but
neither reached their cardiac nor their ventilatory limitation
and were thus assumed to be limited by peripheral muscle
weakness.
Exercise tolerance and muscle force were reduced to
approximately 60% of the predicted value, whereas dyspnea
and fatigue were increased at baseline (Table 2). After 12
weeks of rehabilitation, Wmax increased significantly from
83 ± 40Watt to 103 ± 55Watt and VO2max from 1129 ±
393mL/min to 1345 ± 527mL/min (P < 0.05). 6MWD
improved significantly from 470 ± 88m to 533 ± 85m (P <
0.05) (Table 2). Peripheral and respiratory muscle force also
improved, but only the increase in PImax reached statistical
significance (Table 2). There was a statistically significant
correlation betweenQF andVO2max at inclusion (RS = 0.64;
P = 0.019) (Figure 1).
HRQOL improved at the end of the program signifi-
cantly; CRDQd increased from 17± 5 points to 24± 6 points
and CRDQf from 16 ± 5 points to 18 ± 5 points (P < 0.05)
(Table 2).
After 12 weeks of rehabilitation, improvement exceeding
the minimal clinically significant diﬀerence was reached for
6MWD (59 ± 52m), Wmax (22 ± 25Watt), and CRDQd (7
± 5 points).
25% of the patients exhibited a BMI ≤20 kg/m2 at inclu-
sion (Table 2). At the end of the pulmonary rehabilitation
program, only 10% of patients had a BMI ≤20 kg/m2. FFMI
was reduced in 47% of patients at intake and in 43% of the
patients at the end of the program. There was a statistically
significant correlation between the FFM and VO2max at
baseline (RS = 0.80, P < 0.001) (Figure 2), also between
FFM and Wmax, and 6MWD and QF (RS = 0.86, P < 0.001;
RS = 0.56, P = 0.03; RS = 0.64, P = 0.03).
4. Discussion
This observational pilot study shows that radically treated
patients with respiratory cancer suﬀer from impaired exer-
cise capacity, increased levels of dyspnea and fatigue and
reduced peripheral and respiratory muscle force. Admittedly,
our study was neither randomized, nor controlled. Although
spontaneous recovery could have explained our results,
there is a lot of evidence that radical treatment in lung
cancer patients has downbeat eﬀects on pulmonary function,
exercise capacity, and quality of life, which last for at least 6
months [2, 28]. In some studies, recovery never occurred or
decreases in pulmonary function and 6MWD over time have
been reported [10].
The present study also demonstrates that radically treated
patients for lung cancer experience beneficial eﬀects from
a multidisciplinary pulmonary rehabilitation program, pro-
vided that they present with impaired exercise capacity,
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Table 1: Patient characteristics: Diagnose, Treatment, and Stage.
Patients Age (years) Gender Tumour type Treatment
Post operative
stage
Post operative
Hb (g/dL)
1 67 F
Atypical
carcinoid
tumour
Pneumonectomy + Chemotherapy III A 9.7
2 51 M NSCLC Chemotherapy + Radiotherapy III B 13.1
3 53 M NSCLC Pneumonectomy II A 13.7
4 54 M
Pleural
mesothelioma
Pneumonectomy + Chemotherapy + Radiotherapy III 12.8
5 66 M NSCLC Pneumonectomy + Chemotherapy III A 11.7
6 79 M NSCLC Pneumonectomy III B 11.2
7 66 M
Pleural
mesothelioma
Pneumonectomy + Chemotherapy + Radiotherapy III 12.9
8 66 F NSCLC Lobectomy I B 13.8
9 58 M NSCLC Lobectomy + Chemotherapy III B 14.6
10 70 M NSCLC Lobectomy + Radiotherapy IB 10.8
11 61 M
Pleural
mesothelioma
Pneumonectomy +Chemotherapy + Radiotherapy III 10
12 55 M NSCLC Lobectomy + Radiotherapy IIB 12.4
13 62 M NSCLC Pneumonectomy IIIB 15.5
14 51 M
Pleural
mesothelioma
Pneumonectomy +Chemotherapy + Radiotherapy III 14.6
15 64 F NSCLC Radiotherapy IA 15.8
16 64 M
Typical
carcinoid
tumour
Bilobectomie IA 13
NSCLC: Non Small Cell Lung Cancer.
Table 2: The eﬀects of a 12-week multidisciplinary pulmonary
rehabilitation program.
At baseline
(n = 16)
After 12 weeks
(n = 16) P value
FEV1 (L) 1.8 ± 0.7 1.7 ± 0.6 P = .629
BMI (kg/m2) 23 ± 5 24 ± 5 P = 0.060
VO2max (% pred.) 56 ± 15 66 ± 15 P = 0.022
6 MWD (% pred.) 68 ± 11 78 ± 9 P = 0.003
Quadriceps force (% pred.) 67 ± 17 78 ± 31 P = 0.505
Handgrip force (% pred.) 71 ± 31 74 ± 33 P = 0.209
PImax (% pred.) 54 ± 23 62 ± 19 P = 0.041
FFM (kg) 49 ± 11 51 ± 13 P = 0.025
FFMI (kg/m2) 16 ± 3.0 17 ± 3.0 P = 0.024
CRDQd (points) 17 ± 5 24 ± 6 P = 0.002
CRDQf (points) 16 ± 5 18 ± 5 P = 0.027
FEV1: Forced Expiratory Volume in 1 sec; BMI: Body Mass Index; VO2max:
Maximal Oxygen Consumption; 6MWD: 6-Minute Walking Distance;
PImax: Maximal Inspiratory Pressure; FFM: Fat Free Mass; FFMI: Fat-Free
Mass Index; CRDQd: Chronic Respiratory Disease Questionnaire dyspnea;
CRDQf: Chronic Respiratory Disease Questionnaire fatigue.
fatigue, and dyspnea at inclusion. Interestingly, none of the
previous studies used such strict inclusion criteria as we
did. Actually, this study was conducted because over the last
years patients were increasingly referred by their thoracic
oncologist. We seized that opportunity to assess the eﬀect of
rehabilitation.
VO2max after radical treatment was reduced to 56%
pred. and 6MWD to 68% pred. in our patients. This is in line
with data reported previously in lung cancer patients [8, 9].
It is unclear to which extent the underlying malignancy or
its treatment might have contributed to this reduction in
exercise tolerance. Data by Nezu et al., who observed that
maximal exercise capacity after lung resection did not reach
preoperative values aftermore than 6months, tend to suggest
that the factor “treatment” could have played a prominent
role in this regard [2]. However, the potential contribu-
tion of the cardiovascular, ventilatory, or musculoskeletal
system remains to be systematically investigated in these
patients.
Although studies on the incidence of peripheral and
respiratory muscle weakness after radical treatment for lung
cancer or mesothelioma have not been conducted so far,
we found out that respiratory cancer patients exhibited a
substantial decrease in respiratory and peripheral muscle
force. Indeed in 64% of our patients an abnormally low
QF and in 50% of patients a decreased FFM were observed.
These observations, together with the presence of peripheral
limitation at maximal exercise in half of the patients as
well as the significant correlation between VO2max and
FFM, support the hypothesis that muscle weakness might be
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Figure 2: Correlation between maximal exercise capacity and
muscle mass.
a critically important determinant of exercise limitations in
patients radically treated for respiratory cancer.
Our rehabilitation program consisted of both resistance
and endurance training. Numerous studies have documented
the physiological benefits of resistance training in terms
of increased muscle mass and strength in healthy subjects.
Resistance training increases the cross-sectional area of
the muscle (hypertrophy), allowing the muscle to generate
more force. Peripheral and respiratory muscle strength
increased in the present study, but only PImax reached
statistical significance. Possibly a larger number of sessions
or a more intensive program could have been requested
to transfer the training stimuli into real gains in muscle
force as has been reported after rehabilitation of patients
with COPD and restrictive lung diseases [29, 30]. Another
possible explanation could be that the sample size was too
small to obtain statistically significant improvements for the
peripheral muscles. The increase in Pimax might have been
attributed to the fact that in our series, 60% of patients had
respiratory muscle weakness and were asked to train their
inspiratory muscles every day starting at 30% PImax for 20
minutes. Such improvements have been reported in many
trials in which the eﬀect of IMT has been assessed [23].
It has been suggested that nutritional support in patients
with cancer may improve nutritional status, quality of life,
functional capacity, and lean mass [31]. Our data tend to
support this issue, we systematically prescribed nutritional
support to nutrionally depleted patients, since 70% of
patients received nutritional support, which resulted in as
statistically significant improvement in FFMI and FFM by
2 kg. It remains unclear whether an increase in muscle force
and/or mass might improves the prognosis of these patients,
although loss of skeletal muscle mass is considered to be
a bad prognostic factor. The present findings provide a
rationale to investigate the eﬀect of rehabilitation on survival
in radically treated lung cancer patients.
Although the improvement in QF was not statistically
significant, exercise capacity improved in our patients after
12 weeks. This is in line with the results of an observational
study of inpatient rehabilitation, showing a substantial
improvement of the 6MWD after 8 weeks [8]. A second
study, consisting of an inpatient rehabilitation program of
4 weeks resulted in an improvement of the Borg scale on
exertion, the 6MWD, and the hemoglobin saturation during
the walking test in 25 patients, compared to 186 patients who
had refused to participate in the training group and served
as controls [10]. A third study by Jones et al. also showed
a significant improvement of the exercise tolerance and
HRQOL after 14 weeks of outpatient rehabilitation in radi-
cally treated patients with NSCLC. Our study, which lasted
for 12 weeks, demonstrated much larger improvements in
exercise tolerance in comparison with the results of Jones
et al. (mean diﬀerence VO2max % pred.: 22% versus 4%;
mean diﬀerence Wmax: 22Watt versus 9Watt) [9]. Perhaps
the integration of resistance training in our program might
have caused the present results.
Increases in HRQOL are as important as increases in
physiological outcomes in rehabilitation studies. The CRDQ
has been specially designed for the assessment of HRQOL
in COPD patients. Some of the domains have been used in
patients with restrictive lung disorders [30, 32]. The current
study demonstrated that fatigue and dyspnea decreased
significantly after 12 weeks of rehabilitation. These findings
are highly relevant, since fatigue remains the most frequently
reported symptom in cancer patients and is an important
determinant of a low HRQOL [7]. Studies in patients with
breast cancer indicate that endurance training is themodality
of choice to decrease cancer-related fatigue [6, 7, 33]. In the
present study, a combination of resistance and endurance
training was prescribed, in order to treat both the muscle
weakness and the cancer-related fatigue.
5. Conclusions
Patients with radically treated respiratory cancer suﬀer
from a quite substantial decrease in exercise capacity and
muscle force and an increased level of dyspnea and fatigue.
Significant improvements in exercise capacity, respiratory
muscle force, dyspnea, and fatigue were obtained after a 12-
week multidisciplinary pulmonary rehabilitation program.
The results of the present observational study, consisting of
a small number of patients, require additional confirmation
in larger prospective randomized clinical trials, which may
establish the relevance of rehabilitation in the management
of patients with respiratory cancer. Such studies may also
solve other issues, such as the characteristics of the patients
with respiratory cancer who may benefit most from rehabili-
tation after radical treatment, the duration of a pulmonary
rehabilitation program, the optimal training modality for
these patients, and the importance of nutritional support
remain to be solved.
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